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HISTONE ACETYLATION AND EXPRESSION OF SURVIVAL OF MOTOR 
NEURON (SMN), THE SPINAL MUSCULAR ATROPHY GENE.  Lauren E. 
Kernochan, Nathan S. Woodling, Thanh N. Huynh, Amy M. Avila, Kenneth H. 
Fischbeck, Charlotte J. Sumner. Neurogenetics Branch, National Institute of 
Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD.  
(Sponsored by Stephen M. Strittmatter, Department of Neurology, Yale 




Spinal Muscular Atrophy (SMA) is an inherited neuromuscular disorder 
caused by mutation of the Survival Motor Neuron (SMN1) gene. Embryonic 
lethality is rescued by a nearly identical copy of the gene, SMN2, which exists in 
variable copy number and produces a small quantity of functional SMN protein. 
Because disease severity inversely correlates with SMN2 gene copy number and 
with SMN protein level, one therapeutic strategy has been to increase SMN2 
expression. Previous investigators have demonstrated that SMN promoter 
activity, transcript, and SMN protein are increased in cells treated with histone 
deacetylase (HDAC) inhibitors, suggesting a role for histone acetylation in the 
regulation of SMN expression. 
To further investigate epigenetic regulation of SMN, we used chromatin 
immunoprecipitation to characterize the acetylation state of histones associated 
with the SMN promoter locus.  We show that the SMN promoter has a 
reproducible pattern of histone acetylation conserved across species and tissues.  
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Following treatment with HDAC inhibitors, we correlated a 2-fold increase in SMN 
promoter activity, with an increase in H3 and H4 histone acetylation, particularly 
in upstream regions 2-3 kb from the translational initiation site.  During 
development in mouse tissues, SMN transcript decreased 40-60%, correlating 
with a decrease in histone acetylation levels within the region closest to the 
transcriptional start site.  These data indicate that histone acetylation is a 
biologically relevant determinant of SMN gene expression, and that this 
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Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
disease for which there is currently no treatment.  It is the leading inherited cause 
of infant mortality with an incidence of 1 in 6-10,000 live births and a carrier 
frequency of 1-2% (1-3).  Clinically, SMA is characterized by profound muscle 
weakness in a symmetrical distribution, with proximal muscles more affected 
than distal, and lower extremities more than upper.  In addition to weakness, 
patients often exhibit hypotonia, hyporeflexia and tongue fasciculations (1).  In 
contrast to patients with other neurodegenerative diseases such as amyotrophic 
lateral sclerosis (ALS), the disease course is generally not progressive.  Patients 
with SMA show little or no decline in objective muscle strength after an initial 
phase of decline (1, 4).  Pathologic analysis of spinal cord and muscle from 
human autopsies and mouse models of SMA show a pattern of axonal 
degeneration with subsequent denervation of muscle fibers, although it is not 
clear that particular groups of motor neurons are disproportionately affected (5, 
6). 
SMA is clinically divided into three forms.  SMA type I, or Werndig-
Hoffman disease, is the most severe form and accounts for over 50% of cases.  
These patients present within the first six months of life, are never able to sit 
unaided, and die by the age of 2 years.  In the most severe of these cases, 
mothers will feel a cessation of fetal movement before birth and the infants will 
die within the first few months of life.  Type II patients experience the onset of 
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symptoms within the first 18 months of life, are able to sit but not stand unaided, 
and can live into early adulthood.  Type III patients present later, can have a 
normal lifespan, and are able sit and stand unaided at some point in their lives, 
although they are usually wheelchair bound. Interestingly, patients will usually 
develop normally at first, then plateau, failing to attain developmental milestones 
of strength, rather than experiencing a significant loss of strength.  The primary 
source of mortality in all patients is respiratory failure due to weakness of the 
muscles of inspiration (1, 7). 
Spinal muscular atrophy is caused by deletion or mutation of the Survival 
Motor Neuron (SMN1) gene, located at 5q13 (8).  An inverted near duplicate of 
the gene, SMN2, is present in variable copy number centromeric to SMN1.  Due 
to a C to T base change in a splice-enhancing region of SMN2, 70-85% of the 
mRNA produced from SMN2 is lacking exon 7 (9).  The protein produced from 
the truncated SMN2 mRNA is unstable and thought to be rapidly degraded (10).  
A small fraction of the mRNA produced from SMN2 (15-30%) is full length and 
codes for a fully functional SMN protein, providing enough SMN for cell survival, 
and to prevent the early embryonic lethality seen in species lacking SMN2.  Not 
surprisingly, severity of symptoms in spinal muscular atrophy is inversely 
correlated with SMN2 copy number, and with the amount of SMN protein present 
in the spinal cord (11).   
SMN is a ubiquitously expressed protein with a well-established function in 
splicing (12, 13) and a putative role in mRNA transport (14, 15).  SMN is present 
and necessary for survival in all cells, evoking the question of why motor neurons 
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are uniquely sensitive to low levels of SMN.  The SMN complex, composed of 
SMN and at least 6 gemin proteins, plays an essential role in assembly of small 
nuclear ribonucleoproteins (snRNPs).  SMN has binding sites for gemin-2 
(formerly SMN interacting protein-1 or SIP-1) and for RNA.  It is found primarily in 
the nucleus in discrete “gems”, for gemini of coiled bodies, and is also found at 
the nucleolar membrane and diffusely within the nucleoplasm and cytoplasm 
(12).  More recently, SMN has been visualized at the leading edge of motor 
neuron growth cones (16) and has been shown to associate with the mRNA of β-
actin, suggesting a role for SMN in the enrichment of particular mRNAs 
necessary for developing growth cones (14, 15). 
When observed under the microscope, affected motoneurons from mouse 
models of SMA and from human autopsies display the typical “ballooning” 
phenotype of degenerating neurons (5, 6, 17).  Accumulations of neurofilaments 
have been described, consistent with the hypothesis that cytoskeletal 
disorganization contributes to the pathogenesis of SMA (6).  Reduced 
synaptophysin staining is also observed in affected motoneurons suggesting a 
loss of synaptic contact (5).  Muscle biopsies in SMA can vary widely depending 
on disease severity.  In adults with type III SMA, fibers show typical neuropathic 
changes with fibers that are atrophic and band or triangular shaped in cross 
section, and grouping of type 1 and 2 fibers indicating reinnervation. In a child 
with type I SMA, fibers are smaller in diameter than normal but remain circular, 
without the fiber type-grouping pattern seen with reinnervation. These patterns 
have been correlated electrophysiologically (5, 6).   
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Because of its early onset and lack of significant progression, SMA has 
been postulated to be a disease of development.  In normal individuals, SMN 
protein has been shown to be highly expressed during development, with a 
dramatic decrease in the post-natal period and into adulthood (18).  In embryonic 
chick P19 cells, cellular differentiation to a mature neuronal phenotype is also 
associated with a decrease in SMN levels (19).  Knockdown of SMN mRNA in a 
zebrafish model was found to impair motor axon outgrowth and pathfinding (20).  
Taken together, these data suggest that SMN may play a role in neuronal 
development, and that SMA may in fact be a developmental disorder.  It has 
been postulated that in affected individuals, developmental down-regulation of 
the gene causes SMN protein levels to fall below some absolute threshold, 
resulting in lack of viability in developing motor neurons, and the cessation of 
further development in motor strength.  
Since the recognition that SMA is caused by a lack of SMN protein, 
increasing SMN2 expression has become one of the most promising strategies 
for treatment of SMA (21).  The finding that histone deacetylase inhibitors can 
increase SMN2 expression in vitro, suggested that histone acetylation, an 
important epigenetic determinant of gene expression, might play a role in SMN2 
expression.  Histone deacetylases (HDACs), in conjunction with histone 
acetyltransferases (HATs), control the balance of acetylation of histone H3 and 
H4 “tails” (22).  Increased histone acetylation has been correlated with increased 
gene expression, and decreased acetylation with decreased gene expression 
(22, 23).  This was thought to be due to repel forces between the acetyl groups 
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and the negatively charged phosphate backbone of the DNA, creating more 
space at the site of transcription binding.  More recently, a “histone code” has 
been described in which modifications (acetylation, methylation, phosphorylation, 
and sumoylation) of particular residues on histone amino terminus tails create a 
template for transcription factor binding within a gene’s promoter (24).  Inhibitors 
of HDACs have been shown to increase global histone acetylation, and to alter 
expression in approximately 2% of genes (25).  Several groups have shown that 
compounds which inhibit histone deacetylases can increase SMN2 expression in 
vitro (26-29) and improve survival in vivo (28). Despite their relative 
nonspecificity, HDAC inhibitors are now being evaluated in limited clinical trials 
for use in SMA (21). 
Currently available HDAC inhibitors are known to act on most of the 10 
individual HDACs from classes I and II that have been identified to date.  Class I 
HDACs, including HDACs 1,2,3, and 8, are similar to the yeast RPD3 protein, 
and localize primarily to the nucleus.  Class II HDACs, including HDACs 4,5,6,7,9 
and 10, are similar to the yeast HDA1 protein, and localize to both the nucleus 
and the cytoplasm.  Class III HDACs are the most structurally distinct.  They are 
NAD-dependent enzymes similar to the yeast SIR2 proteins, and are not 
susceptible to inhibition by Trichostatin A, the prototypical HDAC inhibitor (30). 
HDACs are thought to increase SMN expression by activating the SMN 
promoter.   The human SMN1 and SMN2 promoters are nearly identical in 
sequence and activity (9, 19, 31), with a principal transcriptional initiation site 
located 163 bp upstream of the translational initiation site.  Recently, a second 
 
 10
transcriptional initiation site used during fetal development and in undifferentiated 
P19 cells, has been identified at 242 bp, 79 bp upstream of the primary site (32).  
The SMN promoter was originally thought to encompass a 3.4kb region (19), but 
recent data suggests that all the elements needed for activation are present 
within the first 180bp.  Sequences with negative regulatory activity have, 
however, been found as far as 4.6 kb from the translational initiation site (33).  
Mice have a single Smn gene, analogous to our SMN1, which shares sequence 
homology with the human SMN promoters (33, 34).  Transcription factor analysis 
shows likely binding sites for a number of factors, including Sp1, CREB and YY1 
(31).  Recently, Sp and Ets cis-elements, working in combination, have been 




Statement of purpose, specific hypothesis, and specific aims of the 
thesis 
 
The purpose of our study was to investigate the role of histone acetylation 
in expression of SMN.  We hypothesized that histone acetylation would have a 
consistent baseline pattern along the promoter, likely with an increase in 
acetylation close to the site of transcription initiation, as described at other gene 
site (35, 36).  We also hypothesized that an increase in histone acetylation within 
the promoter would correlate with an increase in SMN promoter activation and 
gene expression, and that this effect would be both biologically significant and 
vulnerable to pharmacologic manipulation. 
Specifically, our first aim was to characterize the baseline histone 
acetylation pattern at the SMN promoter using chromatin immunoprecipitation 
with primer-probe sets mapped at ∼500 bp intervals along the promoter and first 
exon.  We mapped promoter histone acetylation in mouse neuronal cells, in 
human fibroblast cells from SMA patients, and in mouse brain, spinal cord, liver 
and kidney tissues.  Although HDAC inhibitors have been previously to increase 
SMN promoter activation, their specific mechanism of action remains poorly 
understood.  We therefore characterized changes in histone acetylation within 
the SMN promoter following treatment with different HDAC inhibitors. 
Next, we characterized the developmental pattern of SMN transcript and 
protein in mice using tissue lysates from brain, spinal cord, liver and kidney 
extracted from mice at E15, P1, P7, P15 and adult (3 month) time points.  We 
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then investigated a correlation between the developmental decrease in SMN 




Materials and Methods:  
 
Cell culture and treatment      
NSC-34 cells, a mouse motor neuron-neuroblastoma hybrid cell line, were 
maintained in Dulbecco’s Minimal Essential Medium containing 5% heat-
inactivated fetal bovine serum, 1% Penicillin-Streptomycin-Gentamicin and 1% 
Geneticin (Gibco, Carlsbad, CA).  These cells are known to express neuronal 
properties including generation of action potentials, and acetylcholine synthesis, 
storage and release (37, 38).  The cells were stably transfected with a 3.4 kb 
fragment of the SMN promoter linked to a β-lactamase reporter gene.  Cells were 
split 1:3 every 2-3 days.   We also used a fibroblast line derived from a skin 
biopsy from a SMA patient with 2 copies of the SMN2 gene (GM03813, Coriell 
Cell Repositories, Camden, NJ, USA).  Fibroblasts were maintained in Minimal 
Essential Medium containing 15% fetal bovine serum and 1% Penicillin-
Streptomycin-Gentamicin.  For experiments, cells were treated with media alone 
or with media containing valproic acid (VPA, Sigma, St. Louis, MO, USA), 
valpromide (VPM, Katwijk Chemie BV, The Netherlands), or suberoylanalide 
hydroxamic acid (SAHA, Calbiochem, San Diego, CA, USA) at the appropriate 
concentration. 
 
Mouse tissue   
C57/Black 6 mice (Charles River Labs, Wilmington, MA) were 
anesthetized with isoflurane and sacrificed by cervical dislocation (P7, P15, and 
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adult) or decapitation (E15 and P1).  Brain, spinal cord, kidney and liver tissues 
were dissected from the mice at ages E15, P1, P7, P15 and three-four months, 
and were flash frozen in liquid nitrogen.  Tissue was thawed on ice immediately 
before use for protein extraction, RNA extraction, or chromatin 
immunoprecipitation. 
 
Promoter activity      
SMN2 promoter activity was measured in transfected NSC-34 cells as a 
function of β-lactamase cleavage of a fluorogenic substrate, CCF-2AM (PanVera, 
Invitrogen, Carlsbad, CA, USA), as previously described (26).  Cells were plated 
500,000 per well in a 96-well plate in serum-free media with or without valproic 
acid or valpromide, and incubated for twenty-four hours.  β-lactamase activity 
was assayed according to the manufacturer’s protocol.  Data is presented as a 
ratio of emission at 460 nm, representing cleaved substrate, over emission at 
530 nm, representing uncleaved substrate. 
 
Protein extraction and Western blotting  
Protein was homogenized in 1 ml of lysis buffer (50 mM Tris-HCl, 0.1% 
Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA [Sigma]) 
and kept at 4º C throughout the extraction process.  Homogenates were 
centrifuged at 4000 rpm for 10 minutes to reduce the foam, sonicated at 35% 
power for 5-10 seconds to lyse the cells, then centrifuged again at 14,000 rpm for 
30 minutes to separate the protein fraction.  Protein concentration was 
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determined by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) according 
to the manufacturer’s instructions.  Protein lysates (10 mg) were denatured in 
sample buffer containing β-mercaptoethanol (Sigma) at 95˚C for five minutes, 
then run on 12% Tris-Glycine gels with SDS Tris-Glycine running buffer 
(Invitrogen) for approximately 1.5 hours at 125 V.  Protein was transferred to 
nitrocellulose membranes in transfer buffer (Invitrogen) at 25 V for 2 hours.  
Nonspecific binding was blocked with 5% (w/v) nonfat dry milk in TTBS.  
Membranes were probed with mouse monoclonal anti-SMN primary antibody at 
1:5000 (Transduction Laboratories, San Diego, CA, USA) then goat anti-mouse-
HRP secondary antibody at 1:2000 (Santa Cruz Laboratories, Santa Cruz, CA, 
USA), and developed with the Western Lightning chemiluminescence system 
according to the manufacturer’s protocol (Perkin-Elmer Life Sciences, Oak 
Brook, IL, USA).  Blots were stripped and re-probed with anti-β actin at 1:2000 
(Sigma), then stripped and blotted a third time with anti-α tubulin at 1:4000 
(Sigma).  Density of bands was determined using NIH Image software. 
 
RNA extraction and quantification   
Tissue was homogenized in 1 ml TRIzol/50-100mg tissue (Invitrogen) and 
spun at 12,000 rpm for 10 minutes to separate the low molecular weight nucleic 
acid fraction.  Cells were washed with PBS and suspended in 1 ml TRIzol.  RNA 
was extracted as previously described (26) using 0.2 ml chloroform/ 1 ml TRIzol.  
After the addition of TRIzol, the samples were vortexed vigorously then 
centrifuged at 12,000 g for 10 minutes at 4˚C.  The aqueous phase was 
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transferred to a fresh tube with 0.5 ml isopropyl alcohol/1 ml TRIzol.  Samples 
were centrifuged at 12,000 g for 10 minutes at 4˚C and the pellet washed once 
with 1 ml of 70% ethanol.  Samples were purified with the RNAeasy clean-up kit 
according to the manufacturer’s protocol (Qiagen, Valenica, CA, USA).  Total 
RNA was quantified by absorption at 260 nm, and 50-ng/5 μL was loaded into 
each 25-μL real time, reverse transcriptase-PCR reaction.  The level of SMN 
RNA was quantified by the ΔΔCt method using 18S as an endogenous control on 
the ABI Prism 7900 in 96-well plates (Applied Biosystems, Foster City, CA, USA).  
SMN primers and probes were 5’ to 3’ as follows: SMN forward: 
GAATGCCACAACTCCCTTG, SMN probe: FAM-CAGTGGAAAGTTGGTGAC-
BHQ, SMN reverse: GCAGCCGTCTTCTGACCAA.  Each reaction contained 
12.5-μl 2X-reaction buffer, 0.9 μl MgSO4, 1.25 μl of 20X ABI primer-probe mix, 
3.1 μl Rox reference dye, 1.75 μl dH2O, 0.5 μl SS-RT Taq, and 5 μl of sample.  
Cycling parameters were: 30 minutes at 45 C and five minutes at 95 C, then 50 
cycles of 15 seconds at 95 C, 1 minute at 60 C.   
 
Chromatin immunoprecipitation      
 Chromatin immunoprecipitation (ChIP) was performed on cells and tissue 
homogenates as previously described (39-41) using 10 ug of antibody to 
acetylated histone subunit H3 (ARTKQTAR AcKSTGG AcKAPRKQLC) or 
acetylated histone subunit H4 (AGG AcKGG AcKGMG AcKVGA AcKRHS-C) 
(Upstate, Lake Placid, NY, USA).   In cell experiments, each condition required 
three 150 mm plates of confluent NSC-34 cells, or twelve 150 mm plates of 
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fibroblasts.  Proteins and DNA in each sample were reversibly cross-linked with 
1% formaldehyde (Sigma), 10-mL/150mm plate of cells or 10 μL/mg of tissue, for 
10 minutes at 37˚C.  Formaldehyde was neutralized by incubation with 1:20 2.5 
M glycine at 37˚C for ten minutes (0.5mL/10mL/150mm plate). 
Samples were washed three times in 2 ml ice-cold PBS and incubated for 
10 minutes on ice in ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl 
pH 8.1).  For in vitro experiments, cell plates were taken to a cold room (4 C), 
where each plate was washed three times in 2 ml ice-cold PBS.  Two milliliters of 
ChIP lysis buffer was then added to each plate and the cells were scraped off the 
plate into the buffer.  The cells, now suspended in buffer, were transferred to 
three 1.5 ml eppendorf tubes for sonication, 500 μl per tube.  DNA was sheared 
by sonication (8 x 15 sec.) yielding 0.5-1 kb fragments of DNA.  Sonication 
efficiency was evaluated in each experiment by running the sonicated chromatin 
on a 1% agarose gel.  The concentration of each sample was determined by 
uncrosslinking 5 μl of sample for one hour at 65˚C in uncrosslinking solution (190 
μl lysis buffer containing 40 mM NaCl + 5 μl proteinase K = 5 μl sample), then 
reading the optical density at 260 nm.  Samples were diluted a minimum of 1:10 
in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
NaCl) to the same final concentration.  Chromatin was pre-cleared with 100 μl of 
salmon sperm agarose A beads per 6 ml chromatin for one hour at 4˚C.  After 
centrifuging at 800 rpm for one minute and removing the chromatin to a fresh 
tube, 50 μL of chromatin was removed to use as an input control and stored at -
80˚C.  For each immunoprecipitation, 1.9 ml of chromatin was incubated 
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overnight at 4˚C with the antibody of choice, or with no antibody (cells) or 
nonspecific IgG (tissue) as a control.  Chromatin and antibody were then 
incubated with 60 μL of salmon sperm agarose A beads for 1 hour and spun 
down at 800 rpm for 1 minute.  Each sample was washed for 5 minutes each in 
low salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mM Tris-HCl pH 8.1, 150 
mM NaCl), high salt (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
pH 8.1, 500 mM NaCl), lithium chloride (0.25 M LiCl, 1% Nonidet P-40, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1) and 2 x TE (10 mM Tris-
HCl, 1 mM EDTA pH 8.0) buffers with 1 min x 800 rpm centrifugation to remove 
each wash.  Chromatin was eluted using 1% SDS in water (250 μl 1% SDS x 15 
minutes at room temperature on rotation).  The beads were centrifuged down 
(1000 rpm x 1 minute), and the elute was removed to a fresh tube with 1 ml 
insulin needles in order to remove all the elute without disturbing the pellet of 
beads.  Elution was repeated in 250 μl 1.5% SDS, and the elute was again 
removed with 1 ml insulin needles and combined with the 1% SDS elute. Input 
samples were thawed and brought to equal volume with 225 μl each of 1% and 
1.5% SDS solution.  Samples and inputs were uncrosslinked in uncrosslinking 
solution (20 μl Tris-HCl pH 6.5, 20 μl 5 M NaCl, 10 μl 0.5M EDTA, 5 μl proteinase 
K) at 65˚ C overnight.  DNA was extracted with an equal volume (500 μl) of 
phenol: chloroform: isoamyl alcohol, 1:1:50, in a gel phase-lock tube (Brinkmann 
Instruments, Eppendorf, Germany) and separated at 14,000 rpm x 15 minutes at 
room temperature.  The organic layer was transferred to two fresh tubes, 250 μL 
each, with 3 volumes (750 μL) of 100% ice-cold ethanol.  After centrifuging at 
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14,000 rpm for 30 minutes, pellets were washed once in 150 μL of 70% ethanol, 
air-dried for one hour, and resuspended in PCR-grade ddH2O. 
Real time PCR with a standard curve was used to quantitate relative 
amounts of DNA.  A standard curve for the human gene was generated from the 
plasmid containing the human SMN2 promoter used to transfect the NSC-34 
cells (Vertex Pharmaceuticals, Cambridge, MA, USA).  Mouse experiments used 
a standard curve generated from dilutions of whole mouse genomic DNA (Santa 
Cruz Biotechnology).  Two separate sets of primers and standards were 
designed for analysis of the human and mouse promoters (Figure 1).  Primers 
and probes were designed to amplify six regions of the human SMN2 promoter, 
labeled here as HuSP1 (for human SMN promoter), HuSP2, HuSP3, and HuSP4 
(Biosource, Camarillo, CA, USA) or six regions of the mouse SMN2 promoter 
and exon 1, labeled here as MSP0 (for mouse Smn promoter), MSP1, MSP2, 
MSP3, MSP4 and MSP5 (see Table 1). Primers for the mouse beta-globin major 
gene were 5’ to 3’ as follows: forward: AGGTGAGGTAGGATCAGTTGCTPCR, 
probe: ACTATGTCAGAAGCAAATGT, reverse: 
GTGCACCATGATGTCTGTTTCTG.  PCR reactions contained an Invitrogen 
master mix (2.5 μL 10X platinum buffer, 1.75 μL 50 mM MgCl2, 0.5 μL 10mM 
dNTP, 1.25 μL of 20X ABI primer-probe mix, 3 μL Rox, 0.125 μL platinum Taq, 
11.825 μL dH2O and 5 μL sample), or an ABI master mix (12.5 μL 2X Universal 
Master Mix, 1.25 μL of 20X ABI primer-probe mix, 6.25 μL dH2O).  PCR cycling 
conditions were: 5 minutes ramping at 95 C, then 40 cycles of 15 seconds at 95 
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C, 1 minute at 60 C.  After subtracting the baseline no antibody control, values 





The SMN gene has a characteristic pattern of histone acetylation 
The chromatin immunoprecipitation assay, known as ChIP, is able to 
measure protein interactions with specific regions of DNA in the native chromatin 
environment.  We used ChIP coupled with real time-PCR to measure the level of 
acetylated H3 and H4 histones associated with the SMN promoter and gene. 
We first examined the histone acetylation pattern of the mouse Smn gene 
in NSC-34 cells, a cell line derived from mouse motor neurons crossed with 
neuroblastoma cells (Figure 2).  This line was chosen for its motor neuron 
characteristics, including the ability to generate action potentials, and to 
synthesize, store and release acetylcholine (37, 38).  For comparison of 
acetylation levels, we used the transcription site region of the mouse β-globin 
gene.  Histone acetylation is well described at this locus as being relatively 
hypoacetylated in tissues where the gene is silent, and hyperacetylated in 
erythroid precursor cells, where the gene is expressed at high levels (42).  We 
found that the regions surrounding the Smn transcriptional initiation site, 
designated MSP3 and MSP4 in the mouse genome, were associated with the 
highest levels of acetylated H3 and H4 histones, in comparison to the regions 
∼1.3-3.5 kb upstream, and ∼1kb downstream.  The hypoacetylated regions of the 
Smn promoter had comparable levels of histone acetylation to the β-globin gene, 
which is transcriptionally silent in this cell type.  We next examined the transgenic 
human SMN2 promoter and gene, stably transfected randomly into the genome 
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of the NSC-34 cell line, and found the same pattern of increased acetylation in 
the region of the transcription site, designated HuSP3 and HuSP4, and less 
acetylation in regions further upstream. 
In order to examine the human SMN gene in its native chromatin 
environment, we performed ChIP experiments on fibroblast cell lines derived 
from skin biopsies of spinal muscular atrophy patients.  In particular, we used the 
3813 line from a patient with type I SMA, known to have 2 copies of SMN2 and 
deletions in the region of exons 7 and 8 in both copies of SMN1.  A similar 
pattern was seen at the SMN promoter in the fibroblasts, as was observed in the 
transgenic SMN2 in the NSC-34 cells.  H3 and H4 acetylation were increased at 
HuSP3 and HuSP4 compared to the rest of the SMN promoter sequence and to 
the β-globin gene transcription locus.  Similar preliminary results were obtained 
from fibroblast cell lines 9677 and 2906, derived from patients with SMA type I 
and II, no SMN1, and with two and four copies of SMN2, respectively (data not 
shown). 
 
Histone deacetylase inhibitors activate the SMN promoter 
Histone deacetylase (HDAC) inhibitors have been previously shown to 
activate the SMN2 promoter in vitro (26, 29), and have been used in limited 
clinical trials as a therapy for spinal muscular atrophy (21).  However, these 
agents change the expression of ∼2% of genes, and it is unknown whether they 
are acting directly at the SMN promoter site.  We therefore investigated changes 
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in H3 and H4 histone acetylation within the SMN promoter region following 
HDAC inhibitor treatment in NSC-34 and 3813 fibroblast cell lines. 
We first confirmed SMN2 promoter activation by treating NSC-34 cells 
with various drugs for 24 hours and measuring promoter activity (Figure 3).  The 
vector stably transfected into the NSC-34 cells contains the 3.4kb putative SMN 
promoter coupled to a β-lactamase gene, such that promoter activation can be 
measured as a function of cleavage of a fluorogenic substrate by β-lactamase.  
We found that valproic acid (VPA) increased promoter activation in a dose-
dependent manner, with a maximum effect of 1.8-fold increased activation over 
untreated cells observed at 2.5 mM VPA, as previously described (26, 29).  
Valpromide (VPM), a structural analog of valproic acid lacking HDAC inhibitory 
activity did not increase SMN promoter activation.  Suberoyl anilide hydroxamic 
acid (SAHA) also increased SMN2 promoter activity in a dose-dependent manner 
by a maximum 2-fold at a concentration of 1 µM.  Similar results have been 
shown for other HDAC inhibitors (26).  Valproic acid has also been shown to 
increase SMN RNA and SMN protein in SMA patient fibroblast cell lines (26). 
In order to test whether activation of the SMN2 promoter by HDAC 
inhibitors is correlated with a change in histone acetylation, we treated NSC-34 
cells for 24 hours with 0, 0.5 or 1.0 μM SAHA, then used ChIP coupled with real 
time PCR to measure H3 and H4 histone acetylation (Figure 4).  We found that 
SAHA increased histone acetylation specifically within the upstream regions 
hypoacetylated at baseline (HuSP1, HuSP2), but not in the downstream regions 
hyperacetylated at baseline (HuSP3, HuSP4) (Figure 7).  A maximum 2.3 fold 
 
 24
increase in H3 histone acetylation over mock treated cells was observed at the 
HuSP1 site after treatment with 0.5 μM SAHA, with no increase observed at 
HuSP4.  A maximum 3.3 fold increase in H4 histone acetylation over mock 
treated cells was observed at the HuSP1 site with 1.0 μM SAHA treatment.  An 
apparent 1.4 fold increase in H4 histone acetylation was observed at HuSP4 at 
this same concentration.  We also treated 3813 fibroblasts with the HDAC 
inhibitor valproic acid for four hours (based on earlier time trial experiments).  
Although these data are not conclusive, we observe a maximum 4.4 fold increase 
in H3 acetylation at HuSP2 with 5 mM VPA treatment, and a maximum 4.5 fold 
increase in H4 acetylation at HuSP1 with 5 mM VPA treatment. 
 
Smn gene expression is developmentally down-regulated  
 Previous investigators have described a decrease in SMN protein levels 
with development (18, 43-45), although this effect has never been well-
characterized at the mRNA level.  Using samples of brain, spinal cord, kidney 
and liver tissue, we measured Smn protein and RNA from three animals at each 
time point: E15, P1, P7, P15, and adult (three-four months). 
 For use in Western blots, protein isolates were quantified in triplicate in 
two separate assays, and band densities were compared to both α-tubulin and β-
actin (Figure 5A,B).  Neither actin nor tubulin was expressed consistently across 
tissue types, with actin significantly less expressed in embryonic liver.  In our 
assay, we observed a 50-85% decrease in Smn protein in every tissue type 
between embryonic and adult time periods, consistent with previous descriptions 
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of Smn in development.  Interestingly, embryonic liver reliably showed a second, 
smaller Smn protein species not seen in other tissues and not previously 
reported in human fetal liver (8).  This species was present with different Smn 
antibodies, and was not present as non-specific staining (data not shown). 
In order to better quantify the change in Smn expression during 
development in different tissues, and to investigate whether this change was due 
to transcriptional or post-translational mechanisms, we measured Smn RNA by 
reverse transcriptase real time PCR (Figure 5C).  Transcript levels were 
analyzed by the ΔΔCt method using two different endogenous controls, 18S and 
β-2-microglobulin, for comparison.  Overall, a ~40-60% decrease in Smn RNA 
was observed in every tissue between E15 and adult ages when compared to 
18S RNA (presented here), and an ~85-95% decrease was observed when 
compared to β-2-microglobulin.  Because 18S was found to increase slightly with 
development, the effect shown in the graph is slightly less than the true change 
measured by Smn alone.  β-2-microglobulin, by contrast, increased slightly with 
development, overestimating the change in Smn transcript (data not shown).  In 
liver, the level of Smn RNA was 30-35% of the other tissues at each time point, 
consistent with the lower levels of Smn protein seen in the Western blots. 
Interestingly, all three spinal cord samples were significantly lower than 
the other two tissues at the P1 time point.  Although there was more variation 
between individual animals at the adult time point, our data suggest that in the 
neural tissues (spinal cord and brain) there is a small increase in Smn expression 
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after the nadir observed at P15, a change that is not present in the non-neural 
tissues (liver and kidney). 
 
Histone acetylation of the SMN promoter during development 
In order to investigate whether histone acetylation plays a role in 
regulating SMN/Smn expression in vivo, we looked for a change in histone 
acetylation associated with the developmental down-regulation of the Smn gene.  
We again used chromatin immunoprecipitation coupled to real time PCR to 
examine histone H3 and H4 acetylation at six points along the mouse Smn 
promoter and intron 1 in neural (brain) and non-neural (liver) tissue from E15 and 
adult mice (Figure 6).  Spinal cord could not be used because the quantity of 
tissue obtained from the embryonic mice was insufficient.  For each chromatin 
preparation, roughly 0.2 mg of tissue was used, requiring up to 6-8 individuals in 
the case of embryonic brain to reach sufficient quantity of material for the assay.  
Each point is the average of at least three chromatin preparations from different 
animals, run in triplicate on each of three 384-well PCR plates. 
Similar to the pattern of histone acetylation observed in NSC-34 and 
fibroblast cell lines, we found that in both liver and brain, the regions immediately 
upstream of the transcription initiation site, MSP3 and MSP4, were relatively 
hyperacetylated compared to regions further upstream in the promoter (MSP0-2), 
and further downstream within the transcribed region (MSP5).  This pattern was 
conserved between brain and liver, and between developmental time points.  In 
both tissues, we found that H3 and H4 histone acetylation were approximately 
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ten times greater in the most acetylated region, MSP4, than in the least 
acetylated regions of MSP0, 1, and 2. 
When comparing embryonic to adult liver tissue, acetylation of histones 
H3 and H4 decreased at the MSP4 site by 34% and 38% respectively, 
corresponding to a 66% decrease in Smn transcript.  In brain, H3 and H4 
acetylation decreased by 21% and 7% respectively, corresponding to a 40% 
decrease in SMN transcript.  Generally, little or no change was observed at other 
sites, except MSP3 and MSP5 where an increase in acetylation was observed, 
primarily limited to H4 in liver.  For comparison, we also measured histone 
acetylation at the transcription initiation site of the mouse β-globin gene.  We 
found that in embryonic liver, a major site of hematopoesis, acetylation of the β-
globin gene is comparable to hyperacetylated regions of the Smn promoter.  
Between E15 and adult samples, acetylation of H3 and H4 histones at the β-
globin gene decreased by 88% and 76%, respectively, corresponding to a >99% 
decrease in transcript levels.   In brain, where the β-globin gene is not expressed 
at any point in development, acetylation of the β-globin gene is equivalent to 






Spinal muscular atrophy is an inherited motor neuron disease for which 
there is currently no treatment.  It is caused by mutation or deletion of SMN1, 
leading to insufficient quantities of full length SMN protein.  One promising 
therapeutic strategy has been increasing expression of the SMN2 gene using 
histone deacetylase (HDAC) inhibitors.  HDAC inhibitors have previously been 
shown to activate the SMN2 promoter, and to increase SMN mRNA and protein 
levels (26, 29).  However, the mechanism of action for the effects observed with 
HDAC inhibitors is not understood, and the role of histone acetylation in directly 
regulating SMN expression has never been explored.  Here, we use chromatin 
immunoprecipitation to look at baseline histone acetylation within the SMN/Smn 
promoter, and then investigate changes in that baseline associated with gene 
expression changes.  We show for the first time that histone acetylation within 
the SMN/Smn promoter changes in a site-specific manner following HDAC 
inhibitor treatment in vitro, and in association with developmental down-
regulation of the gene in vivo. 
First, a characteristic pattern of histone acetylation is established which is 
conserved across cell lines, species, and tissue types.  Histones associated with 
the translational initiation site are hyperacetylated at both H3 and H4 histone 
tails, compared to regions >1 kb upstream, or downstream within exon 1.  This 
pattern is consistently observed in mouse motor neuron cells, both in the mouse 
endogenous gene and the human transgene, in human fibroblasts derived from 
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SMA patients, and in mouse tissue from brain, spinal cord, liver, and kidney in 
both embryonic and adult mice.  This pattern of greater histone acetylation 
surrounding the initiation site is consistent with other active genes studied, for 
example, in the active human interferon-β (35) and mouse β-globin genes (46).  
In genome wide studies of yeast and Drosophila, histones in the 5’ transcribed 
region of active genes are generally hyperacetylated compared to histones within 
the gene or in more distant regulatory sequences (36, 47). 
Interestingly, this region immediately surrounding the translation initiation 
site, is the region previously identified as the minimal functional promoter region 
(19).  More recently, Rouget et al. refined the minimal functional promoter 
sequence to 15 bp upstream and 117 bp downstream of the transcriptional start 
site for the human SMN gene, and 46 bp upstream and 125 bp downstream of 
the transcriptional start site for the mouse Smn gene.  In their work, inclusion of 
upstream sequence in promoter constructs reduces promoter activity, suggesting 
that upstream regions may be involved in repressor activity (32).  This is 
supported by Boda et al. who found regions with repressor activity as far as 
4.6kb upstream (33). 
The sequence of the core promoter region is conserved between the 
mouse and the human genomes, and contains binding sites for numerous 
transcription factors, including cAMP-response element binding protein (CREB) 
and Sp (32, 48).  The CREB family of transcription factors, in particular, is known 
to recruit the highly potent histone acetyltransferase, p300/CREB binding protein 
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(CBP) (49), suggesting that recruitment of p300/CBP to the SMN promoter could 
be responsible for the high acetylation levels observed in this region. 
Next, the 1.7 to1.9- fold increase in SMN/Smn promoter activity previously 
observed with HDAC inhibitor treatment (valproic acid and SAHA), is found to 
correspond with an increase in H3 and H4 histone acetylation within the 
SMN/Smn promoter region.  According to our data, histone deacetylase inhibitors 
have a specific effect on the acetylation of H3 and H4 histones located further 
upstream at sites hypoacetylated at baseline, and no measurable effect on 
histones associated with the translational initiation site. These data suggest that 
HDAC inhibitors do have an effect within the region of the SMN promoter, but not 
at the transcription site, raising the question of whether the HDAC-induced SMN 
promoter activation is a direct effect, or secondary to upregulation of some other 
molecule, such as a transcription factor.  Alternatively, it is known that HDACs 
not only deacetylate histones but also non-histone proteins that are 
transcriptional regulators (30).  Thus, HDAC inhibitor treatment could result in 
acetylation and activation of a DNA binding factor that recruits HATs and leads to 
acetylation of the SMN2 gene in upstream regions. 
In order to examine the biological significance of histone acetylation in 
regulation of SMN/Smn expression, experiments were shifted to an in vivo 
system, mouse tissue from different developmental time points.  Although SMN 
protein has long been known to be developmentally down-regulated (18), we 
present the first rigorous quantitation of this effect at the mRNA level.  A 40-60% 
decrease in SMN RNA is seen in all tissues between E15 and adult (three 
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month) mice.  Interestingly, both the SMN protein and RNA are lower in liver 
tissue, 30-35% of other tissues, at every developmental time point.  The 
significance of this finding is not known.  One limitation of our study is the use of 
whole tissue lysates.  It has been show by in situ hybridization that the 
distribution of SMN in the spinal cord changes with development from being more 
diffuse to being specifically concentrated in motor neurons (50), an effect which 
is not appreciated in our method.  Of note, we found that SMN levels in the spinal 
cord dropped significantly more than other tissues at the P1 time point (∼20%), 
suggesting that down-regulation of SMN may take place earlier in spinal cord 
than in other tissues, and may therefore be subject to different regulatory 
mechanisms.  Recently, this finding was corroborated in experiments using 
sucrose centrifugation followed by western blot, in which the authors show that 
the decrease in SMN RNA corresponds to the process of myelination in the 
spinal cord, which occurs earlier than in the brain (51). 
Finally, we correlated this developmental change in expression with a 
change in histone acetylation within the Smn promoter.  At the MSP4 site, the 
region closest to the transcriptional and translational initiation sites, we observed 
a decrease in acetylated H3 and H4 levels in liver tissue, and a decrease in H3 
acetylation in brain tissue.  This was associated with a 40-60% decrease in Smn 
mRNA, as measured by real time RT-PCR.  Although the observed decrease in 
acetylation is modest, studies in other genes have noted similarly small changes 
in acetylation associated with large changes in gene expression.  The mouse β-
globin gene is perhaps the best studied, in which gene induction produced only a 
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two-fold increase in H3 acetylation in association with a 150-fold increase in 
expression.  Within neighboring regions in the Smn promoter and gene, MSP5 
and MSP3, small increases in H3 and H4 acetylation were observed.  However, 
we believe the decrease at MSP4 is the most relevant as this is the most 
transcriptionally active region of the gene.  Furthermore, in more recent 
experiments, this developmental, regionally specific decrease in acetylation has 
been associated with a large increase in HDAC2 and a smaller increase in 
HDAC1 within the same region (52). 
Although chromatin immunoprecipitation is a powerful technique, its limit 
of detection does not extend below 500 bp.  Thus the alternate transcription 
recently described by Rouget et al. as a site used preferentially during 
development could not be distinguished in our work, as it is only 79 bp away from 
the adult transcription initiation site (32).  It may be that histone acetylation 
changes locally within regions smaller than our 500 bp limit of detection. 
There has been some controversy in the literature about the use of HDAC 
inhibitors as a treatment for spinal muscular atrophy, in particular because of 
their lack of specificity, requirements for high doses, and as yet poorly 
understood site of action.  As mentioned previously, HDAC inhibitors affect the 
expression of approximately 2% genes.  They also seem to act on most of the 
known class I and II HDACs, including those HDACs that act on non-histone 
proteins and are located predominantly outside the nucleus (30).  HDAC 
inhibitors have also been explored for their ability to change the expression of 
numerous other genes, including tumor suppressor and oncogenes (reviewed in 
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(53), so there is a theoretical risk of activating repressed oncogenes and 
increasing the incidence of cancer.  Valproic acid is used as an anti-epileptic 
medication because of its effect on sodium channels, at a maximum dose of 60 
mg/kg/day resulting in serum levels of 50 -100 μg/ml.  Even at this dose, which is 
lower than the dose required for HDAC inhibition, valproic acid is a known 
teratogen and can cause numerous side effects, including mental status 
changes.  It has been postulated that HDAC inhibition increases SMN expression 
by increasing histone acetylation at the SMN promoter, and although the data 
presented here support this idea, this has not been proven.  Given the need for 
high doses, and the poorly understood, nonspecific nature of our current arsenal 
of HDAC inhibitors, long-term treatment with high doses of these drugs is likely to 
cause significant immediate and long term side effects, and we cannot predict 
what these will be. 
To address some of these questions, experiments are underway to test 
the safety and feasibility of HDAC inhibitor treatment in a mouse model of spinal 
muscular atrophy.  Further ChIP experiments are also underway using antibodies 
against individual HDACs, particularly those in class I, which are concentrated in 
the nucleus, in order to determine which particular HDACs may be acting at the 
SMN promoter locus.  ChIP can also be used to determine other proteins present 
at the SMN promoter, for example bound transcription factors or histone 
acetyltransferases (HATs).  Also important will be to determine the relative 
activity of particular inhibitors against individual HDACs, and whether more 
specific inhibitors can be developed to target the HDACs active in controlling 
 
 34
SMN.  Together these experiments may allow more specific targeting of the 
histone acetylation machinery at the SMN gene locus. 
The histone acetylation system described here is only one of the many 
epigenetic determinants that may be relevant to the expression of SMN.  
Methylation, phosphorylation and sumoylation are well-described histone 
modifications known to affect gene expression individually, and to interact with 
histone acetylation in controlling gene expression (24, 54).  In addition to 
affecting immediate transcription factor binding and chromatin accessibility, 
histone acetylation is also known to influence long term expression controls such 
as DNA methylation.  Methylated DNA and the methylation-specific transcription 
repressor, MeCP2 have been shown to recruit histone deacetylases (55).  
Conversely, treatment with the HDAC inhibitor Trichostatin A, has been reported 
to induce loss of methylation at specific genes (56).    Further, a number of 
heavily methylated genes studied in vitro have been reported to be unresponsive 
to the HDAC inhibitor Trichostatin A without pretreatment with a demethylating 
agent (reviewed in (57).  These data suggest that treatment with a demethylating 
agent plus an HDAC inhibitor may increase the expression of SMN beyond what 
each agent can do individually.  The effect may even be synergistic, and could 
allow the use of lower doses of HDAC inhibitors in the treatment of spinal 
muscular atrophy. Further experiments investigating the contributions of other 




In conclusion, we have shown that SMN has a reproducible pattern of 
histone acetylation that is modified by HDAC inhibitor treatment and during the 
course of development.  Together, these data strongly suggest that histone 
acetylation plays an important role in SMN/Smn regulation and that this 
epigenetic determinant can be manipulated pharmacologically.  However, this 
work represents a proof of concept, and significant work will be required before 
we can hope to exploit this knowledge to have an impact on the course of the 
disease.  In particular, future experiments should concentrate on investigating 
how to more specifically target the histone acetylation machinery at the SMN 
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